Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
221.31
-8.90 (-3.87%)
Feb 20, 2026, 10:19 AM EST - Market open
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
$711,121
Profits / Employee
-$225,181
Market Cap
13.58B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 5,800 |
| BioMarin Pharmaceutical | 3,040 |
| Genmab | 3,029 |
| Jazz Pharmaceuticals | 2,800 |
| Exelixis | 1,077 |
| Ionis Pharmaceuticals | 1,069 |
| Roivant Sciences | 750 |
| BridgeBio Pharma | 730 |
ASND News
- 8 days ago - Ascendis Pharma FY 2025 Results: More Than A Takeover Story - Seeking Alpha
- 8 days ago - Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 15 days ago - Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 - GlobeNewsWire
- 5 weeks ago - Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript - Seeking Alpha
- 6 weeks ago - Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - GlobeNewsWire